Glioblastoma multiforme (GBM) is a WHO grade IV brain tumor with aggressive growth and frequent recurrence, and temozolomide (TMZ) remains the standard first-line chemotherapy despite limited durable benefits. Parthenolide (Pt), a sesquiterpene lactone derived from the medicinal plant feverfew, has shown antitumor activity in multiple cancer types; however, its therapeutic potential and downstream mechanisms in GBM have not been fully defined. Herein, we demonstrate that Pt induces apoptosis, suppresses stemness, and reduces invasion in human U-87MG and T98G cells. Pt also potentiates TMZ's efficacy in vitro and in an orthotopic GBM model with male NOD-SCID mice. RNA-sequencing and pathway analyses revealed that Pt markedly represses epithelial-mesenchymal transition (EMT)-associated programs. Among the most significantly downregulated genes, transgelin-2 (TAGLN2) emerged as a key Pt-responsive target, and its high expression was correlated with poor survival in glioma cohorts. TAGLN2 overexpression rescued Pt-mediated suppression of malignant phenotypes and the EMT, supporting a functional role for TAGLN2 in Pt responsiveness. Mechanistically, inhibitor screening identified glycogen synthase kinase-3β (GSK3β) as a critical upstream regulator of Pt-induced TAGLN2 repression. Promoter-reporter and ChIP-qPCR assays further showed that Pt activates GSK3β, leading to reduced cyclic AMP response-binding protein (CREB) transcriptional activity and diminished CREB occupancy at the TAGLN2 promoter, thereby suppressing TAGLN2 transcription. Collectively, our findings define a Pt-driven GSK3β/CREB/TAGLN2 axis that restrains the mesenchymal transition and enhances TMZ sensitivity in GBM, highlighting TAGLN2 and its upstream regulatory pathway as potential therapeutic targets for this lethal disease.